Ongoing Projects

European flagAROMICS has a clear international vision. From its inception, the company has participated in the establishment of a biotechnology strategy in Europe to improve commercial and production activities of small and medium size companies.

AROMICS has proven experience in R&D Projects under various funding programs: European (Horizon 2020), national (CDTI) and local (ACC1Ó-FEDER). The active participation of the company in European funded R&D projects as well as membership in different European platforms enables the company to:

  • Be at the forefront of European research.
  • Identify, improve and implant new technologies with potential applications in the health sector(industry and clinical practice).
  • Favor technology transfer.
  • Share the costs of innovation through partnerships with other biotechnology and pharmaceutical companies.

The aim of the project is to develop a novel treatment for Malignant Mesothelioma, a rare, aggresive and poorly responsive cancer directly related to asbestos exposure. General objective pursued by the project include to complete non-regulatory preclinical studies and conduct a clinical trial in patients.

(Co-financed by the Horizon 2020 Programme of the European Union)

(Co-financed by CDTI through the Horizon Europe EIC Accelerator Seal of Excellence SME Programme)

G4-CANCER

G4-CANCER

The aim of the project is to develop an innovative platform for screening anti-tumour drugs, based on the identification and characterisation of G-quadruplex (G4) structures in oncogenes. These structures, which are complex and highly regulatory in nature, play a key role in both tumour progression and mechanisms of resistance to conventional therapies, and are therefore therapeutic targets of great interest.

(Cofinanced by the program  NUCLIS D’INNOVACIÓ TECNOLÒGICA Projectes de Recerca Industrial i Desenvolupament Experimental - ACCIO 2022)